Northwest Biotherapeutics Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
February 4, 2013
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Austin Stephenson
Re: | Northwest Biotherapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-185898
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Northwest Biotherapeutics,, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4 p.m., Eastern Standard Time, on Tuesday, February 5, 2013, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
NORTHWEST BIOTHERAPEUTICS, INC.
By:/s/ Linda F. Powers
Name: Linda F. Powers
Title: Chief Executive Officer